IMAGENT
LOE Approachingdimyristoyl lecithin; perflexane
NDAINTRAVENOUSINJECTABLE
Approved
May 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 6d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IMAGENT (dimyristoyl lecithin; perflexane) is an intravenous injectable diagnostic agent approved in 2002. It is a microbubble-based contrast agent used for cardiac imaging to enhance ultrasound visualization. The drug works by creating echogenic microbubbles that reflect ultrasound waves, improving image quality during cardiac procedures.
LOE Approaching
Product faces loss of exclusivity with moderate competitive pressure (30%), signaling a shrinking commercial team and transition toward value-based positioning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
IMAGENT careers are limited; zero linked job openings suggest minimal hiring and team size contraction. This is an appropriate opportunity only for professionals seeking transition roles or managed decline experience in a mature diagnostic product.
Brand ManagerMedical Science Liaison
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.